There can't be many people in the hedge fund industry that could comfortably say they know what makes a good investment in the realm of biotechnology.
The producers in the industry are necessarily cagey about what they are working on, and most, if not all, hedge fund managers probably wouldn't fully understand it. Most investors, that is.
Michael Walsh, founder of Kilkenny Capital Management, is different. Not just another hedge fund manager, he is a chemist with a Harvard MBA who can shed lig
The week on Risk.net, December 9–15 2017Receive this by email